Background: Eptifibatide (Integrilin) is an intravenous (IV) peptide drug that selectively inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug, however has a short half-life. Therefore, antithrombotic agents like eptifibatide are required to become improved with a protected and targeted delivery system such as using nano-liposomes to the site of thrombu...

Background: Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the aggregation of activated platelets. The peptide drugs are encapsulated into nanolipisomes in order to decreasing their side effects and improving their half-life and bioavailability. Objectives: In this study, the in vitro cytotoxicity and hemocompatibi...

Random Forests (RF) is a successful classifier exhibiting performance comparable to Adaboost, but is more robust. The exploitation of two sources of randomness, random inputs (bagging) and random features, make RF accurate classifiers in several domains. We hypothesize that methods other than classification or regression trees could also benefit from injecting randomness. This paper generalizes...

conclusions the authors describe the second reported case of eptifibatide-induced severe thrombocytopenia associated with cardiac surgery. in this case, discontinuation of eptifibatide and transfusion of apheresis platelets increased the platelet count (137 k/ul) the following day, and the patient subsequently underwent successful coronary artery surgery using cardiopulmonary bypass. introducti...

Background—Patients with a recent episode of non–ST-segment elevation acute coronary syndrome before CABG have higher rates of operative morbidity and mortality than patients with stable coronary syndromes. The efficacy of administering eptifibatide to these patients undergoing in-hospital CABG is unknown. Methods and Results—The Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppr...

The role of small molecules anti-glycoprotein (GP) IIb/IIIa pharmacotherapy during acute myocardial infarction (AMI) has not been established. The purpose of our study was to evaluate the clinical outcomes of patients sustaining AMI who underwent emergent percutaneous coronary intervention (PCI) and who were distinguished by the use of the anti-GP IIb/IIIa agent eptifibatide. We studied a conse...

Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,000 cells/mm(3)) within a few hours of receiving the drug. This case report discusses a patient who de...

BACKGROUND AND PURPOSE Despite systemic heparinization, thromboembolic complications remain a major concern related to endovascular treatment of intracranial aneurysms. We assessed the safety of intravenous eptifibatide administered during aneurysm coiling procedures to prevent such complications. METHODS From August 2001 to November 2004, 298 coil embolization procedures were performed to tr...

BACKGROUND Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown. METHODS We compared a strategy of early, routine administration of eptifibatide with delayed, provisional administration in 9492 patients who had acute coronary syndromes without ST-segmen...